As of September 30, 2026, Lucid Diagnostics Inc. carries a market capitalization of 143.42M, placing it among publicly traded companies globally. Its enterprise value stands at 143.92M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 143.42M |
| Enterprise Value | 143.92M |
Lucid Diagnostics Inc.'s next confirmed earnings release is scheduled for March 29, 2027.
| Earnings Date | 3/29/2027 |
As of September 30, 2026, Lucid Diagnostics Inc. has 190.97M shares outstanding.
| Shares Outstanding | 190.97M |
These figures are as of September 30, 2026. The price-to-sales ratio is 23.37, and the price-to-book ratio stands at 24.18.
| PS Ratio | 23.37 |
| PB Ratio | 24.18 |
| P/TBV Ratio | 24.18 |
| P/FCF Ratio | -2.45 |
| P/OCF Ratio | -2.47 |
These figures are as of September 30, 2026. The EV/Sales ratio of 26.47 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 143.92M versus a market cap of 143.42M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 26.47 |
As of September 30, 2026, Lucid Diagnostics Inc. maintains a current ratio of 1.20, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 311.65, indicating elevated leverage, while an interest coverage ratio of -2,960.12 demonstrates limited ability to service its debt obligations.
| Current Ratio | 1.20 |
| Quick Ratio | 0.87 |
| Debt / Equity | 311.65 |
| Debt / EBITDA | -0.37 |
| Interest Coverage | -2,960.12 |
These figures cover the twelve months ended September 30, 2026. Return on assets (ROA) is negative at -119.77, reflecting losses generated across the asset base. The company generates approximately 66,304.88 in revenue per employee across its workforce of 82.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 12.59 indicates how many times Lucid Diagnostics Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Assets (ROA) | -119.77 |
| Revenue Per Employee | 66,304.88 |
| Employee Count | 82.00 |
| Inventory Turnover | 12.59 |
As of the close on November 16, 2026, Lucid Diagnostics Inc.'s stock has declined approximately 62.82% over the past 52 weeks. The 50-day moving average sits at 0.59, while the 200-day moving average is 0.98.
| 52-Week Price Change | -62.82% |
| 50-Day Moving Average | 0.59 |
| 200-Day Moving Average | 0.98 |
Over the twelve months ended September 30, 2026, Lucid Diagnostics Inc. generated 5.44M in revenue and converted that into -48.54M in net income, yielding earnings per share of -0.29. EBITDA reached -50.32M, while operating income came in at -51.20M.
| Revenue | 5.44M |
| Gross Profit | -897,000.00 |
| Operating Income | -51.20M |
| Pretax Income | -48.54M |
| Net Income | -48.54M |
| EBITDA | -50.32M |
| EBIT | -51.20M |
| Earnings Per Share (EPS) | -0.29 |
As of September 30, 2026, Lucid Diagnostics Inc. holds 17.99M in cash and equivalents against 18.49M in total debt, resulting in a net debt position of -693,000.00. Total book value stands at 5.93M, with working capital of 4.32M providing operational flexibility.
| Cash & Cash Equivalents | 17.99M |
| Total Debt | 18.49M |
| Net Debt | -693,000.00 |
| Equity (Book Value) | 5.93M |
| Book Value Per Share | 0.03 |
| Working Capital | 4.32M |
Lucid Diagnostics Inc. produced -51.53M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -304,000.00 in capital expenditures, free cash flow totaled -51.83M - equivalent to -0.31 per share.
| Operating Cash Flow | -51.53M |
| Capital Expenditures | -304,000.00 |
| Free Cash Flow | -51.83M |
| FCF Per Share | -0.31 |
Over the twelve months ended September 30, 2026, Lucid Diagnostics Inc. posted a gross margin of -16.50, reflecting its pricing power and cost economics. The operating margin of -941.73 and net profit margin of -892.75 provide insight into operational efficiency.
| Gross Margin | -16.50 |
| Operating Margin | -941.73 |
| Pretax Margin | -892.75 |
| Profit Margin | -892.75 |
| EBITDA Margin | -925.55 |
These figures cover the twelve months ended September 30, 2026. The dividend payout ratio of 20.80 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -40.79: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.68, meaning Lucid Diagnostics Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Payout Ratio | 20.80 |
| Shareholder Yield | -15.68 |
| FCF Yield | -40.79 |
As of September 30, 2026, Lucid Diagnostics Inc. has an Altman Z-Score of -17.81, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -17.81 |